Spyre Therapeutics (SYRE) Return on Invested Capital (2022 - 2023)
Historic Return on Invested Capital for Spyre Therapeutics (SYRE) over the last 4 years, with Q3 2025 value amounting to 0.44%.
- Spyre Therapeutics' Return on Invested Capital rose 900.0% to 0.44% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.44%, marking a year-over-year increase of 900.0%. This contributed to the annual value of 0.57% for FY2024, which is 14800.0% up from last year.
- According to the latest figures from Q3 2025, Spyre Therapeutics' Return on Invested Capital is 0.44%, which was up 900.0% from 0.41% recorded in Q2 2025.
- Spyre Therapeutics' Return on Invested Capital's 5-year high stood at 46.24% during Q2 2023, with a 5-year trough of 1.88% in Q1 2023.
- For the 4-year period, Spyre Therapeutics' Return on Invested Capital averaged around 3.06%, with its median value being 0.53% (2024).
- In the last 5 years, Spyre Therapeutics' Return on Invested Capital soared by 474400bps in 2023 and then crashed by -468200bps in 2024.
- Quarter analysis of 4 years shows Spyre Therapeutics' Return on Invested Capital stood at 1.44% in 2022, then skyrocketed by 743bps to 9.23% in 2023, then crashed by -105bps to 0.47% in 2024, then rose by 7bps to 0.44% in 2025.
- Its last three reported values are 0.44% in Q3 2025, 0.41% for Q2 2025, and 0.4% during Q1 2025.